碳酸镧对维持透析患者高磷血症的疗效分析  

EFFECT OF LANTHANUM CARBONATE ON HYPERPHOSPHATEMIA IN DIALYSIS PATIENTS

作　　者：陈林[1] 刘日光[1] 陈浩雄[1] 陈磊[1] 傅君舟[1] 

机构地区：[1]广州市第一人民医院,广东广州510180

出　　处：《现代医院》2014年第7期36-37,40,共3页Modern Hospitals

基　　金：广州市科技计划项目(编号83078)

摘　　要：目的探讨碳酸镧对维持透析患者高磷血症的短期疗效及耐受性。方法回顾性分析2012年10月～2013年10月在我院使用碳酸镧治疗高磷血症透析患者（血液透析或腹膜透析）的临床资料。结果共入组22例患者,其中男13例,女9例,腹膜透析4例,血液透析18例,平均年龄（54.2±15.1）岁,平均透析龄（51.5±21.4）月。治疗前、治疗12周后血磷,血清校正钙、钙磷乘积、iPTH为：（2.94±0.43）vs（2.31±0.39）（p=0.00）,（2.23±0.11）vs（2.26±0.10）（p=0.25）,（82.2±12.9）vs（65.3±11.1）（p=0.00）,（1 462±1 053）vs（1 411±943）（p=0.51）。不良反应主要为胃肠道反应,发生率36.4%,无1例患者因严重不良反应退出。结论碳酸镧是一种对维持透析患者短期疗效好、不良反应轻,耐受性良好的口服磷结合剂。Objective To Investigate the short-term efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia in dialysis patients. Methods The clinical data of dialysis patients（ hemodialysis or peritoneal dialysis）with hyperphosphatemia who were given with lanthanum carbonate treatment from October 2012 to October 2013 in our hospital were retrospectively analyzed. Results A total of 22 cases were enrolled. Of all the 22 cases,there were 13 cases of males,9 cases of females; 4 cases of peritoneal dialysis,and 18 cases of hemodialysis. Their average age was（54. 2 ±15. 1） years,and their average dialysis age was（51. 5 ± 21. 4） months. Before the treatment and 12 weeks after the treatment,serum phosphorus,corrected serum calcium,calcium- phosphorus product and iPTH were（2. 94 ± 0. 43） vs（2. 31 ±0. 39）（p = 0. 00）,（2. 23 ± 0. 11） vs（2. 26 ± 0. 10）（p = 0. 25）,（82. 2 ± 12. 9） vs（65. 3 ± 11. 1）（p = 0. 00）,（1 462± 1 053） vs 1 411 ± 943）（p = 0. 51）. The main adverse reactions were gastrointestinal reactions. The incidence of adverse effects was 36. 4%. No patient quitted from this study for safety reason. Conclusion Lanthanum carbonate is a well- tolerated oral phosphate binder with a good short- term curative effect and light adverse reactions in treatment of hyperphosphatemia in dialysis patients.

关 键 词：碳酸镧 高磷血症 透析 磷结合剂 

分 类 号：R459.5[医药卫生—治疗学]